Skip to content

Author

K. Selvendiran

We have 2 of 114 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Inhibition of Translesion DNA Synthesis Sensitizes BRCA-Deficient Ovarian Cancer to PARP Inhibitors.

It is demonstrated that TLS, particularly Polη-dependent bypass, is a critical mechanism enabling replication fork rescue and survival under PARPi therapy, and targeting TLS provides a promising therapeutic strategy to augment PARPi efficacy and prevent resistance in BRCA-deficient ovarian cancer.

Na Li, Kousalya Lavudi, Qian-Yun Ge et al. · 0 citations
Open access Aug 2026

A Scalable Bioreactor Platform for Reproducible Production and Characterization of Ovarian Cancer-Derived Extracellular Vesicles

This study provides a practical serum-free CELLine AD 1000 workflow for generating characterized OC-related EV material for downstream analytical studies and indicates higher per-collection EV particle recovery with the bioreactor.

Wei Fu, K. Dorayappan, Colin L. Hisey et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.